CSIMarket
 
Cognition Therapeutics inc   (CGTX)
Other Ticker:  
 
 
Price: $2.0900 $0.11 5.556%
Day's High: $2.1599 Week Perf: 8.29 %
Day's Low: $ 1.90 30 Day Perf: 6.09 %
Volume (M): 274 52 Wk High: $ 3.49
Volume (M$): $ 573 52 Wk Avg: $1.77
Open: $2.01 52 Wk Low: $0.90



 Market Capitalization (Millions $) 63
 Shares Outstanding (Millions) 30
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 0

Cognition Therapeutics Inc
Cognition Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative disorders, particularly Alzheimer's disease. The company aims to target the underlying mechanisms of cognitive decline and develop small molecule drugs that can restore cognitive function and slow disease progression. Cognition Therapeutics' innovative approach involves disrupting the interaction between a protein called Sigma-2 receptor and amyloid beta, a protein associated with Alzheimer's disease. By inhibiting this interaction, the company hopes to prevent the toxic effects of amyloid beta and potentially improve memory and cognition in affected individuals.


   Company Address: 2500 Westchester Ave. Purchase 10577 NY
   Company Phone Number: 481-2210   Stock Exchange / Ticker: NASDAQ CGTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cognition Therapeutics Inc

Company Expenses Surge in Fourth Quarter Earnings Report

Cognition Therapeutics Inc, a clinical-stage company specializing in neurodegenerative disorder treatments, has been making significant strides in the biotechnology and pharmaceutical sector. The recent announcement of the successful closing of their underwritten public offering, which brought in gross proceeds of approximately $11.5 million, has caught the attention of industry veterans and investors alike.
With the influx of funds from the public offering, Cognition Therapeutics is well-positioned to further their research, clinical development, and manufacturing of product candidates. These funds will also be allocated towards working capital, capital expenditures, and general corporate purposes, signaling a strong commitment to advancing their pipeline of treatments for neurodegenerative disorders.

Shares

Cognition Therapeutics Closes $11.5M Public Offering, Boosting Neurodegenerative Disorder Research: Share Performance Analyzed

Published Thu, Mar 14 2024 8:05 PM UTC



In an exciting development, Cognition Therapeutics, a clinical-stage company specializing in neurodegenerative disorder treatments, has successfully closed its underwritten public offering of common stock. With an impressive gross proceeds of approximately $11.5 million, the company aims to utilize these funds to further their research, clinical development, and ma...

Shares

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

Published Tue, Mar 12 2024 12:16 AM UTC



Cognition Therapeutics, a clinical-stage company focused on developing innovative treatments for neurodegenerative disorders, has recently made headlines with its announcement of a successful public offering of common stock. The company priced 6,571,428 shares at $1.75 per share, with an option for the underwriters to purchase an additional 985,714 shares on the sa...

Product Service News

Cognition Therapeutics Commences Underwritten Public Offering of Common Stock to Accelerate Development of Neurodegenerative Disorder Therapies

Published Mon, Mar 11 2024 8:06 PM UTC

Cognition Therapeutics Plans Public Offering of Common Stock to Advance Neurodegenerative Disorder TreatmentsPURCHASE, N. Y., March 11, 2024 - Cognition Therapeutics, a clinical stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative disorders, has announced its intention to undertake an underwritten public offering of its common stoc...

Product Service News

Unveiling the Power of Proteomics: Cognition Therapeutics Presents Groundbreaking Findings Linking CT1812 Treatment Effect to Protein Markers in Alzheimer's Disease Studies

Published Wed, Mar 6 2024 12:30 PM UTC

Cognition Therapeutics Presents Groundbreaking Analyses Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies at AD/PD 2024 ConferenceCognition Therapeutics, a clinical stage biotechnology company focused on developing novel treatments for neurodegenerative disorders, has recently presented significant findings at the AD/PD 2024 Alzhe...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com